Henlius Biopharmaceutical

Overview

16-year-old Hong Kong-listed China biopharmaceutical company that pioneered biosimilars in China, earned the first EMA approval from China, adopted single-use technology early, and is executing a dual-engine biosimilar-and-innovation strategy. Henlius has 10 marketed products approved in over 70 countries, with all three of its manufacturing sites currently located in China and active exploration of outside-China manufacturing networks underway. Henlius was the first company approved for biosimilars in China, the first from China to receive EMA approval, and helped write China's CDE biosimilar development guidelines. (Segment 8 (35:00-40:00))